Vaxart Inc (VXRT) Stock Price, Quote & News

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influ...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 550 3500

Fax: 650 871 8580

Website: vaxart.com

Address:

170 Harbor Way, Suite 300, South San Francisco, United States

WALTERPAYTON34 Sep. 14 at 10:44 PM

$VXRT I think we actually will have increased our NO votes

0 · Reply

BrutisWalter Sep. 14 at 10:35 PM

$VXRT No Way they got the Votes ,No Way Just MHO that's it !

0 · Reply

geomurp514 Sep. 14 at 10:29 PM

$VXRT Very interesting, our BOD’s have a boat load of unjust incentive options vesting September 22nd. If they intend on selling it will be OTC. Justice!

0 · Reply

79Auprah Sep. 14 at 10:19 PM

$VXRT I see lots of money being donated to shareholder causes with good intentions, but ultimately with no oversight, accountability, or transparency. Instead, how about we give some of those funds to EVERYONE’S favorite StockTwits poster. You know who I’m talking about. The man, the myth, the legend…@Harpua97. Let’s raise money to cover the losses that will be incurred thanks to the ‘no’ voters harming his stock holdings and forcing Vaxart to languish on the OTC. It’s the least we can do! No amount is too much when it comes to showing our support for this beloved and (I can only assume) extremely handsome gentleman. Dig deep, folks. I’m hard-pressed to think of a more noble cause, and I’m sure that everyone here agrees. I’m hoping that even @SoldDaPopinski will find it in his heart to give away some of the money he’s convinced others to hand over. Together we can make a difference!

1 · Reply

7xbagger Sep. 14 at 9:30 PM

$VXRT reverse your name, then compliment yourself... Another BS'ter.. same guy? WTFC.. blocked....

1 · Reply

7xbagger Sep. 14 at 9:27 PM

$VXRT Always, always always check the date... you can tell a new scammer by the date...

0 · Reply

WILVAR21 Sep. 14 at 9:25 PM

$VXRT KNEEPADS,your a comedy show..VOTE NO TO REVERSE SPLIT

2 · Reply

amessagefromtheodd Sep. 14 at 8:47 PM

$VXRT Vaxart anticipates releasing data from the 400-person sentinel cohort of its COVID-19 Phase 2b trial in the first quarter of 2026. January, February or March 2026 It would be nice if RFK/FDA/BARDA really tighten the leash around Lo/BOD… Or the drama continues?

0 · Reply

enalpa Sep. 14 at 8:42 PM

$VXRT Looking through weekend chats: Harpua has gone through quite a transformation from guy here to support R/S. 1. First he was only here to defend the R/S because it was best for the SH. 2. Then he spent most of his time defending Lo. 3. Now he spends time attacking guys on this board.

3 · Reply

Kher33 Sep. 14 at 7:53 PM

$VXRT member since 8/23/25 hmmm

3 · Reply

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Sep 10, 2025, 9:00 AM EDT - 4 days ago

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Sep 8, 2025, 8:00 AM EDT - 6 days ago

Vaxart Announces Adjournment of Special Meeting of Stockholders

Sep 2, 2025, 4:30 PM EDT - 12 days ago

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

Sep 2, 2025, 9:00 AM EDT - 12 days ago

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Aug 21, 2025, 9:30 AM EDT - 24 days ago

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Aug 13, 2025, 9:01 PM EDT - 4 weeks ago

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 5:25 PM EDT - 4 weeks ago

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Jul 24, 2025, 4:01 PM EDT - 7 weeks ago

Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq

Jun 13, 2025, 4:52 PM EDT - 3 months ago

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Jun 11, 2025, 7:30 AM EDT - 3 months ago

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Jun 10, 2025, 4:47 PM EDT - 3 months ago

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Jun 2, 2025, 4:20 PM EDT - 3 months ago

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 29, 2025, 4:05 PM EDT - 3 months ago

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025, 8:00 AM EDT - 3 months ago

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 28, 2025, 8:00 AM EDT - 3 months ago

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 27, 2025, 8:00 AM EDT - 3 months ago

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 20, 2025, 5:00 PM EDT - 4 months ago

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025, 8:00 AM EDT - 4 months ago

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 15, 2025, 8:00 AM EDT - 4 months ago

Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 14, 2025, 4:05 PM EDT - 4 months ago

Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine

May 13, 2025, 8:43 PM EDT - 4 months ago

Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 4 months ago

Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

May 13, 2025, 4:01 PM EDT - 4 months ago

Vaxart Appoints Jeroen Grasman as Chief Financial Officer

May 12, 2025, 8:00 AM EDT - 4 months ago

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

May 5, 2025, 8:00 AM EDT - 4 months ago

Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress

May 2, 2025, 8:00 AM EDT - 4 months ago

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Apr 30, 2025, 8:00 AM EDT - 4 months ago

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Apr 16, 2025, 8:00 AM EDT - 5 months ago

Vaxart to Present at World Vaccine Congress Washington 2025 on April 23

Apr 16, 2025, 8:00 AM EDT - 5 months ago

Vaxartto Present at World Vaccine Congress Washington 2025 on April 23

Mar 20, 2025, 6:25 PM EDT - 6 months ago

Vaxart, Inc. (VXRT) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:01 PM EDT - 6 months ago

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Mar 11, 2025, 8:00 AM EDT - 6 months ago

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate

Mar 5, 2025, 4:05 PM EST - 6 months ago

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

Jan 13, 2025, 7:55 PM EST - 8 months ago

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Dec 2, 2024, 4:01 PM EST - 10 months ago

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Nov 13, 2024, 6:19 PM EST - 10 months ago

Vaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 10 months ago

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

Sep 30, 2024, 4:12 PM EDT - 1 year ago

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Aug 15, 2024, 1:57 PM EDT - 1 year ago

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Aug 8, 2024, 8:51 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding

Jun 17, 2024, 4:05 PM EDT - 1 year ago

Vaxart Provides Business Update

Jun 13, 2024, 7:07 PM EDT - 1 year ago

Vaxart Announces $40 Million Underwritten Offering of Common Stock

Jun 13, 2024, 4:15 PM EDT - 1 year ago

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

May 13, 2024, 5:49 PM EDT - 1 year ago

Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:01 PM EDT - 1 year ago

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

WALTERPAYTON34 Sep. 14 at 10:44 PM

$VXRT I think we actually will have increased our NO votes

0 · Reply

BrutisWalter Sep. 14 at 10:35 PM

$VXRT No Way they got the Votes ,No Way Just MHO that's it !

0 · Reply

geomurp514 Sep. 14 at 10:29 PM

$VXRT Very interesting, our BOD’s have a boat load of unjust incentive options vesting September 22nd. If they intend on selling it will be OTC. Justice!

0 · Reply

79Auprah Sep. 14 at 10:19 PM

1 · Reply

7xbagger Sep. 14 at 9:30 PM

$VXRT reverse your name, then compliment yourself... Another BS'ter.. same guy? WTFC.. blocked....

1 · Reply

7xbagger Sep. 14 at 9:27 PM

$VXRT Always, always always check the date... you can tell a new scammer by the date...

0 · Reply

WILVAR21 Sep. 14 at 9:25 PM

$VXRT KNEEPADS,your a comedy show..VOTE NO TO REVERSE SPLIT

2 · Reply

amessagefromtheodd Sep. 14 at 8:47 PM

0 · Reply

enalpa Sep. 14 at 8:42 PM

3 · Reply

Kher33 Sep. 14 at 7:53 PM

$VXRT member since 8/23/25 hmmm

3 · Reply

1BudgetTrader Sep. 14 at 5:57 PM

$VXRT P2/2 Gray matter 2... There's an "important" date that is coming shortly after the Oct 6 date to enact the RS to meet the Oct 17 requirement 3 date. On Oct 7 the P2b hits 12 months for the first participants dosed. And there's a reason that I put important in quotes. Vaxart used interesting wording in their clinical trial endpoints, up to "approximately" 12 months. To confirm my thoughts, I ran it thru 2 AI's, and here's the response. Yes, absolutely — a duration of 10 to 12 months would reasonably fit the description of “approximately 12 months” for a clinical trial. As you can see, we officially enter that Gray zone on Sept 26 for all participants to surpass 10 months. With a little help from our friends at BARDA/FDA, and maybe RFK, we could get the sentinel cohort data in time to meet NASDAQ's 3rd requirement as long as we release the data prior to Oct 6. And there's always the next appeal to extend the timeline. Good luck longs... starting the week on a positive note...

2 · Reply

pauliedeee Sep. 14 at 5:50 PM

$VXRT https://www.washingtonpost.com/health/2025/09/14/vaccine-innovation-investment-rfk-jr/ For anyone that has a subscription, make sure to leave a comment in the comment section. This is only the beginning.

1 · Reply

79Auprah Sep. 14 at 5:46 PM

$VXRT How may times does Harpua need to be right before people start paying more attention? He may well be the smartest man I’ve ever met… and I met Stephen Hawking once!

1 · Reply

79Auprah Sep. 14 at 5:44 PM

$VXRT Is Harpua the Handsome onto something here? It does seem pretty shady…

2 · Reply

Harpua97 Sep. 14 at 5:42 PM

$VXRT Harpua nails it again… Do you guys really not see the empty words about just being a humble shareholder, while he keeps very significant secrets and decides what you guys can and can’t know? Not to mention the suspicious spending and lack of any accounting of how your donations have been spent. If Dan isn’t the leader (which he is), then why not democratize information and give all of the shareholders on here the full story? If he’s not in charge, why does he get to decide what you know and what you don’t know? You guys don’t have to like me, but don’t let the messenger prevent you from hearing the message. Again, don’t take my word for it. Ask Dan yourself and see if you get a clear answer. You won’t. Now ask yourself why?

1 · Reply

WALTERPAYTON34 Sep. 14 at 5:28 PM

$VXRT he lied

0 · Reply

Harpua97 Sep. 14 at 5:27 PM

$VXRT Today is Day 3 of your leader refusing to tell you what he’s keeping secret while collecting you donations. He’s glad to take your money, but he’s leaving you in the dark. @SoldDaPopinski, has your attorney written a carefully worded response for the group yet? One where you carefully dodge giving direct answers? Why won’t you tell us if (a) Lo has reached out to you; (b) if you’ve engaged in talks with Lo/BOD/leadership; and (c) if you’ve accepted anything of value from the company as part of a special arrangement? And how about sharing an accounting of how those donations are being spent? You’ve got a nice new fancy Edge subscription. Have you done any recent travel? Paid your attorney for certain things that haven’t been disclosed? Why don’t you respect your loyal followers enough to just be honest with them? What do you have to hide? 🤔 You chose to take the mantle as the leader of this (misguided) movement, and when the dust clears, you’ll be the face of this entire saga. No one voted for you, but you were savvy enough to grab power. Good for you, but how about some transparency for your fans, followers, and donors?

0 · Reply

1BudgetTrader Sep. 14 at 5:27 PM

$VXRT P1 It's all about the gray matter/s... Gray matter 1... Vaxart failed the first requirement for Nasdaq to relist... but we're still voting on a RS... would Nasdaq accept only meeting requirements 2 & 3? If the RS is voted down again... would Nasdaq accept only meeting requirement 3? If Nasdaq doesn't accept either of these two scenarios, when would Vaxart's next appeal happen... if they decide to even appeal again? If Nasdaq is willing to accept the first scenario and the RS is voted down again, will Vaxart extend the vote for another week? That would take us to the last day to meet requirements 2 & 3. But if the RS was still voted down, would Nasdaq be willing to accept the second scenario, because regaining the $1 compliance is really the end game of this whole thing? Does Vaxart have any tricks up their sleeve? Remember Ed jumping in to clarify what Lo said about their meeting with Nasdaq? The RS was the only proposal brought forward... And that takes us to another gray matter.

0 · Reply

Harpua97 Sep. 14 at 5:16 PM

$VXRT If he’s not your leader, then what would you call the guy who gets all of the press, speaks publicly on behalf of the group, receives your donations to pay for HIS attorney (and maybe his newfound Edge subscription), and decides which bits of information the commoners deserve to hear and what to keep for himself? I’d say that’s your leader. Not necessarily a good leader, but your leader nonetheless. Again, just ask Dan to answer the three questions and see if you get a direct answer. You won’t, because HIS attorney is advising HIM on what to do. You guys are just his pawns and his piggy bank.

0 · Reply

nowiseegood Sep. 14 at 5:14 PM

$VXRT Looking for a positive here...we have a living example for the "Just Say No" to drugs campaign.

1 · Reply

Nik_CA Sep. 14 at 5:09 PM

$VXRT Harpua is losing his marbles and maybe his job as he couldn't sway the votes in favor of RS proposal.

1 · Reply

Harpua97 Sep. 14 at 5:03 PM

$VXRT Very humble words… while still keeping big secrets from the commoners and collecting money from them. Slick move!

0 · Reply

Market Cap	97.49M
Revenue (ttm)	28.70M
Net Income (ttm)	-66.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-233.28%
Debt to Equity Ratio	0.00

Volume	11,568,300
Avg Vol	5,416,006
Day's Range	N/A - N/A
Shares Out	228.31M
Stochastic %K	7%
Beta	1.14
Analysts	Strong Sell
Price Target	$4.67